Healthcare Industry News: Cerecor
News Release - June 13, 2013
Cerecor Appoints Federica F. O’Brien as Chief Financial Officer
BALTIMORE--(Healthcare Sales & Marketing Network)--Cerecor Inc., a biotechnology company developing neuroscience drugs that target underserved patient segments of common diseases, today announced the appointment of Federica F. O’Brien, CPA, as Chief Financial Officer.“Freddi has demonstrated leadership in financial and operational management for both public and private life science companies, making her an ideal addition to the experienced Cerecor team,” said Blake Paterson, Cerecor’s Co-founder and Chief Executive Officer. “We look forward to her contributions as we work to build further value for our shareholders.”
“I am excited to become a part of Cerecor’s leadership team,” commented Freddi O’Brien, Cerecor’s Chief Financial Officer. “By focusing on programs for which there is human proof of concept and designing trials with tailored measurement tools, Cerecor’s approach to product development increases the likelihood of success.”
Ms. O’Brien joins Cerecor from Cervilenz Inc., a privately held medical device company, where she was Chief Financial Officer and Chief Operating Officer. While at Cervilenz, Ms. O’Brien raised capital, expanded the patent portfolio worldwide and was instrumental in obtaining CE marking and ISO 13485 certification for a women’s healthcare device. Previously, Ms. O’Brien was Chief Financial Officer of privately-held Cardiokine Inc., a biotechnology company developing compounds for the treatment and prevention of cardiovascular disease. She helped raise $87 million through venture funding and played a central role in establishing a collaboration agreement which provided Cardiokine with significant funding for development. During 2004, Ms. O’Brien was integral to the IPO at Barrier Therapeutics, where she served as Controller. Earlier in her career, she was Chief Financial Officer of Infonautics, Inc, a publicly held technology based company, and began her career in public accounting, most recently at Coopers & Lybrand (PWC).
About Cerecor
Driven by an innovative team of industry experts and leading scientists, Cerecor aspires to develop neuroscience drugs that will make a difference. We are committed to improving the lives of patients by addressing underserved segments of common diseases. We are focused exclusively on developing products that have human proof-of-concept in either the target or the molecule and possess biomarkers to guide development, and our clinical strategies employ the latest technologies to improve the likelihood of trial success.
www.Cerecor.com
Source: Cerecor
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
